Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Alnylam Elects Amy Schulman to its Board of Directors

Published: Saturday, July 05, 2014
Last Updated: Saturday, July 05, 2014
Bookmark and Share
Appointment of industry leader brings broad strategic, commercial, and legal experience to board.

Alnylam Pharmaceuticals, Inc. has announced the election of Amy W. Schulman to its Board of Directors. Ms. Schulman is the former Executive Vice President and General Counsel of Pfizer Inc., and served as the Business Unit Lead for Pfizer's Consumer Healthcare business. She currently serves on the faculty of Harvard Business School as a Senior Lecturer.

"Amy is a recognized leader in the development and growth of global pharmaceutical businesses, and she will bring this expertise to our Board as we continue to build Alnylam as a leading biotechnology company. As the former General Counsel at Pfizer, Amy also brings deep legal expertise to our Board," said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. "Given our robust clinical progress and our potential transition to a commercial company in the coming years, Amy's addition to our Board comes at an opportune time as we advance RNAi therapeutics to patients."

"I am excited to join the Board of Alnylam, a first-in-class innovation-based biotechnology company, and a pioneer in advancing an entirely new class of high impact medicines with RNAi therapeutics," said Ms. Schulman. "The tremendous progress Alnylam has made in its clinical efforts has yielded very encouraging results. I look forward to working with the outstanding team of management and directors in place today and contributing to the company's value creation strategy and execution."

Ms. Schulman originally joined Pfizer in 2008 as General Counsel and saw the company through its $68 billion acquisition of Wyeth. In 2010, in addition to her role as General Counsel, Ms. Schulman became President and General Manager of Pfizer's $2.1 billion global infant formula and nutrition business. Once that business was sold to Nestlé she assumed responsibility for the Consumer Healthcare business.

Before joining Pfizer, she was a partner at DLA Piper, where she was a member of the Board and Executive Policy Committees, and built and led the international law firm's mass tort and class-action practice. Ms. Schulman's accomplishments have earned her recognition from leading publications and organizations.

In 2013 Fortune magazine named her one of the "50 Most Powerful Women in Business." That same year, The American Lawyer named her one of the "Top 50 Innovators," and The National Law Journal named her one of "The 100 Most Influential Lawyers in America."

The American Bar Association honored her with the Margaret Brent Women Lawyers of Achievement award in 2012. A Phi Beta Kappa graduate of Wesleyan University, Ms. Schulman earned her J.D. from Yale Law School in 1989. She serves on the Board of Directors of The Brookings Institution and Wesleyan University.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Alnylam Announces USPTO Issues Patent Covering RNAi Therapeutics
New '277 McSwiggen patent includes broad, sequence-independent claims for chemically modified siRNAs targeting the HBV genome.
Saturday, June 14, 2014
Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5
Company on track to file IND application in late 2014 and now guides to report initial clinical results in mid-2015.
Thursday, June 12, 2014
Alnylam Initiates Phase II Clinical Trial with ALN-TTRsc
Company expects to present data in late 2014, and start pivotal phase III trial with ALN-TTRsc in TTR cardiac amyloidosis in late 2014.
Monday, December 30, 2013
Alnylam Presents New Pre-clinical Data on ALN-AT3
New results demonstrate an expanded therapeutic index for AT knockdown and complete correction of aPTT in models of hemophilia.
Tuesday, December 10, 2013
Alnylam Files CTA to Initiate a Phase I Study for ALN-AT3
Company expects to initiate phase I study in early 2014 with interim data from hemophilia subjects by year-end 2014.
Friday, November 01, 2013
Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic
New research demonstrates potent, dose-dependent, and durable silencing of serum C5 for the treatment of complement-mediated diseases.
Friday, June 21, 2013
Alnylam Reports Positive ALN-TTR02 Clinical Data
Results of clinical study demonstrate rapid, dose-dependent, durable, and specific knockdown of TTR, the disease-causing protein in TTR-mediated Amyloidosis (ATTR).
Tuesday, July 24, 2012
Alnylam and Collaborators Publish New Pre-clinical Results
New paper published in blood shows potent and selective induction of liver erythropoietin through silencing of EglN genes.
Wednesday, June 13, 2012
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
Self-Assembling, Biomimetic Membranes May Aid Water Filtration
A synthetic membrane that self assembles and is easily produced may lead to better gas separation, water purification, drug delivery and DNA recognition, according to an international team of researchers.
Error Correction Mechanism in Cell Division
Cell biologists have reported an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
Researchers Resurrect Ancient Viruses
Researchers at Massachusetts Eye and Ear and Schepens Eye Research Institute have reconstructed an ancient virus that is highly effective at delivering gene therapies to the liver, muscle, and retina.
Cell Aging Slowed by Putting Brakes on Noisy Transcription
Experiments in yeast hint at ways to extend life of some human cells.
Crucial for Stem Cell Survival Protein Identified Using Editing Tool CRISPR
A team of University of Wisconsin-Madison engineers has identified a protein that is integral to the survival and self-renewal processes of human pluripotent stem cells (hPSC).
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!